

HOBART GROUP *at a Glance*

Our aim is to help develop new and improved ways to manage growing global demands related to chronic disease. We develop and commercialize medical technologies, specifically targeting chronic disease markets with significant unmet needs. With group offices in Hamilton (Bermuda), Geneva (Switzerland) and Beijing (China), our growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation.

Innovation benefiting humanity

200+ employees

across our companies

1,000+ patents

& applications by our inventors

\$200M+

investments in our portfolio

10+ products launched

across our companies

1M+ patients treated

with products developed by us

\$1B+ exits

in a dozen companies

The team

Our portfolio is managed by a team of experienced industry executives:

Shlomo Ben-Haim MD, Founder and Chairman

Simos Kedikoglou MD, CEO of Impulse Dynamics and former Corporate VP of Business Development at Boston Scientific

Adrian Gilmore, CEO of MetaCure and former President of Terumo Medical Products

9 Hobart companies

Impulse Dynamics

Dedicated to offering innovative medical device solutions for the treatment of chronic heart failure.

MetaCure

Dedicated to the development and commercialization of a minimally-invasive treatment for type 2 diabetes.

Motorika

Develops and commercializes robot-assisted solutions to meet the therapeutic needs of patients suffering from variety of neurological conditions.

FlowMedic

Developer of innovative miniaturized portable leg compression devices for the treatment of PAD and prevention of DVT.

Molecular Dynamics

Developing innovative imaging technologies and advanced clinical applications.

Renal Dynamics

Dedicated to treating hypertension through its third-generation renal denervation system.

EPD Solutions

Committed to improving the efficacy and efficiency of minimally-invasive catheter-based procedures for the treatment of cardiac arrhythmia.

Lavita Technologies

An early stage neuromodulation company, focused on development of the Nexion™ system for treatment of autoimmune inflammatory diseases.

OncoD

An early stage company developing a suite of navigation and ablation tools for treating solid tumors.

Our track record: 8 public and acquired companies

Novocure / Corindus / Disc-O-Tech Biosense-Webster / Radiancy Spectrum Dynamics / InStent X-technologies